Global /United States /Healthcare /Biotechnology /LIANY

LianBio

LIANY

• OTCMKTS: LIANY • Delayed

0.1220USD 0%

As of 13 June 2026, LianBio has a market cap of $13.2M USD, ranking #39756 globally and #5210 in the United States. It ranks #3545 in the Healthcare sector, and #693 in the Biotechnology industry.

Global Rank

39756

Country Rank

5210

Sector Rank

3545

Industry Rank

693

Key Stats

Market Cap

$13.2MUSD

EBITDA (TTM)

-$105.26MUSD

Net Income (TTM)

-$87.98MUSD

PB Ratio

0.1

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Adam Stone open_in_new

Employees

163

Founded

2019

Website

lianbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	0.3%	-26%	31%	74%	28%	-36%	-94%	-99%

News

Markets

Exchange	Ticker	Price	Quotes
OTC Markets (OTCMKTS / OTC) MIC: OTCM PRIMARY	LIANY LianBio ADR ISIN: US53000N1081 Shares Out.: Shares Outstanding: 109.126M¹ Shares Float: 109.067M² TV: TradingView: OTC: LIANY SA: Stock Analysis: OTC: LIANY YF: Yahoo Finance: LIANY GF: Google Finance: OTCMKTS: LIANY BA: Barron's: LIANY MS: Morningstar: PINX: LIANY	0.1220 USD	TV: TradingView: OTC: LIANY SA: Stock Analysis: OTC: LIANY YF: Yahoo Finance: LIANY GF: Google Finance: OTCMKTS: LIANY BA: Barron's: LIANY MS: Morningstar: PINX: LIANY

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About LianBio

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 1M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 1M%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 209K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 199K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 190K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 137K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 362K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 340K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 321K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 320K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 213K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 195K%	-	Germany

chevron_leftBack